These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 38139207)

  • 1. Oncolytic Viruses in the Era of Omics, Computational Technologies, and Modeling: Thesis, Antithesis, and Synthesis.
    Menotti L; Vannini A
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
    Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
    Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model.
    Senekal NS; Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
    Bull Math Biol; 2021 May; 83(7):75. PubMed ID: 34008149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
    Menotti L; Avitabile E
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
    Feola S; Russo S; Ylösmäki E; Cerullo V
    Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option.
    Asija S; Chatterjee A; Goda JS; Yadav S; Chekuri G; Purwar R
    Front Immunol; 2023; 14():1118246. PubMed ID: 37006286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?
    Groeneveldt C; van den Ende J; van Montfoort N
    Cytokine Growth Factor Rev; 2023 Apr; 70():1-12. PubMed ID: 36732155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of oncolytic virus in tumor therapy.
    Huang Z; Guo H; Lin L; Li S; Yang Y; Han Y; Huang W; Yang J
    J Med Virol; 2023 Apr; 95(4):e28729. PubMed ID: 37185868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
    Sadri M; Najafi A; Rahimi A; Behranvand N; Hossein Kazemi M; Khorramdelazad H; Falak R
    Int Immunopharmacol; 2023 Sep; 122():110470. PubMed ID: 37433246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
    Nguyen HM; Bommareddy PK; Silk AW; Saha D
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The two-faces of NK cells in oncolytic virotherapy.
    Marotel M; Hasim MS; Hagerman A; Ardolino M
    Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cells and oncolytic viruses: joining forces against cancer.
    Moreno R
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalizing Oncolytic Immunovirotherapy Approaches.
    Stergiopoulos GM; Iankov I; Galanis E
    Mol Diagn Ther; 2024 Mar; 28(2):153-168. PubMed ID: 38150172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma.
    Monie DD; Bhandarkar AR; Parney IF; Correia C; Sarkaria JN; Vile RG; Li H
    Neurosurg Focus; 2021 Feb; 50(2):E10. PubMed ID: 33524942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Viruses in Cancer Treatment: A Review.
    Lawler SE; Speranza MC; Cho CF; Chiocca EA
    JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.